BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on the discovery and development of breakthrough therapies for cardiovascular and muscle disease based on microRNA biology, today announced the publication of novel research demonstrating that acute myocardial infarction (MI) in mice and humans results in the dysregulation of a specific set of microRNAs.
